AstraZeneca bets another $140 mln on Moderna's "messenger" drugs

LONDON, Aug 10 (Reuters) - AstraZeneca has invested another $140 million in Moderna Therapeutics, the U.S. biotech "unicorn" which already has a cash pile of around $1 billion and is developing drugs based on a molecule known as messenger RNA.